A5061793266- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Protein Degradation and Inhibitors
- Brain Metastases and Treatment
- Advanced X-ray and CT Imaging
- Childhood Cancer Survivors' Quality of Life
- Cancer, Hypoxia, and Metabolism
- PARP inhibition in cancer therapy
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Radiotherapy Techniques
- DNA Repair Mechanisms
- Digital Radiography and Breast Imaging
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
The University of Texas MD Anderson Cancer Center
2020-2024
Trinity College Dublin
2024
St. James's Hospital
2014-2024
National Cancer Institute
2006-2024
University of Liverpool
2022
Beaumont Hospital
2011-2021
Royal Marsden Hospital
2016-2021
Institute of Cancer Research
2016-2021
Royal Marsden NHS Foundation Trust
2016-2021
St. Vincent's University Hospital
2015-2018
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it unclear whether multicellular CTC clusters generated this disease they can bypass the physical hurdle of blood-brain barrier. Here, we assessed presence composition at multiple time points 13 patients with progressing during an open-label phase 1/2a study microtubule inhibitor BAL101553. We observe...
The term “undruggable” is used to describe a protein that not pharmacologically capable of being targeted; recently, however, substantial efforts have been made turn these proteins into “druggable” targets. Thus, “difficult drug” or “yet be drugged” are perhaps more appropriate terms. In cancer, number elusive targets fall this category, including transcription factors such as STAT3, TP53, and MYC. Pharmacologically targeting intractable now key challenge modern drug development, requiring...
Abstract Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept recombinant fusion protein comprising human VEGF receptor extracellular domains fused to immunoglobulin G1. HIF‐1α inhibition in combination with anti‐angiogenic therapy promising anti‐tumor strategy. This Phase 1 dose‐escalation/expansion study assessed safety/ tolerability sapanisertib ziv‐aflibercept advanced solid tumors. Methods Fifty‐five patients heavily pre‐treated metastatic...
In head and neck squamous cell carcinoma (HNSCC), HRAS mutation is a new actionable oncogene driver. We aimed to evaluate mutational variants, comutation profile, survival outcomes of this molecularly defined population.We leveraged four deidentified patient data sets with HRAS-mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, American Association for Research GENIE v.12. Patient demographic information clinical courses were extracted, when available, in...
Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin thought to inhibit the mTOR pathway through upstream activation 5'-AMP-activated protein kinase (AMPK) suggesting combination therapy may enhance antitumor activity sapanisertib. We report preliminary safety, tolerability, and efficacy from dose-escalation study sapanisertib in with metformin patients advanced solid tumors.
The history of performance testing in Leeds television fluoroscopic systems is briefly outlined. Using the visual, physical and technological requirements as a basis, set nine test objects for quality control fluoroscopy described. factors measured by are listed introduction: their function fully described remainder paper. objects, conjunction with oscilloscope, give both subjective objective information about X-ray system. Three enable physicist or engineer to adjust certain aspects...
Abstract Leeds Test Object TOR[MAM] has been designed to supplement the current FAXIL mammography test object TOR[MAX]. It contains a range of details that have more natural radiographic appearance and as closely approximates image quality achieved in clinical mammography. Physical aspects design implementation are presented. The used preliminary physical evaluation comparative qualities produced by conventional (screen–film) photostimulable phosphor computed results discussed. TOR[MAX] also...
e13022 Background: ACTH-producing pituitary carcinomas (APPC) are malignant neuroendocrine tumors affecting the adenohypophysis. They extremely rare, with a poor prognosis. poorly responsive to chemotherapy and radiotherapy. We report case of 25 year old female diagnosis APPC, metastatic bone, treated temozolamide, followed by bevacizumab novel agent, pasireotide. Methods: The patient was diagnosed in 2002 an ACTH-secreting macroadenoma causing Cushing’s disease. Despite two transphenoidal...